Exicure To Co-develop Burixafor With Adbiotech For Multiple Indications

April 23, 2026 — 11:29 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Exicure Inc. (XCUR), an early-stage biotechnology company, announced on Thursday a co-development agreement with Korean biotechnology company Adbiotech Co. Ltd., for combination therapies with Burixafor in treating haematological indications.

Burixafor (GPC-100) is an investigational drug developed to treat varied indications such as sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors. It previously completed a successful Phase 2 clinical trial for multiple myeloma, and is currently being explored for other haematological indications.

As part of the agreement, Adbiotech will conduct in vitro studies for preclinical validation and translational research, while Exicure is expected to lead clinical and regulatory strategy for the drug's development.

The companies are directing efforts toward studies enabling an investigational new drug (IND) submission for burixafor.

XCUR is currently trading at $3.64, up 0.05%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Exicure To Co-develop Burixafor With Adbiotech For Multiple Indications

Tags

Latest Articles